SRR934826
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 115.53876478318003
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.351
- NOTCH_SIGNALING+0.325
- ANDROGEN_RESPONSE+0.291
- MYC_TARGETS_V1+0.289
- E2F_TARGETS+0.284
- HEDGEHOG_SIGNALING+0.274
- UNFOLDED_PROTEIN_RESPONSE+0.273
- MITOTIC_SPINDLE+0.267
- TGF_BETA_SIGNALING+0.259
- OXIDATIVE_PHOSPHORYLATION+0.257
Top 10 suppressed
- ANGIOGENESIS-0.271
- KRAS_SIGNALING_DN-0.228
- MYOGENESIS-0.197
- APICAL_SURFACE-0.162
- ALLOGRAFT_REJECTION-0.161
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.158
- SPERMATOGENESIS-0.129
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.125
- PEROXISOME-0.081
- ESTROGEN_RESPONSE_LATE-0.053
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934756 | — | — | 0.923 |
| 2 | C7284164-EF9A-4BF0-AE88-571A0BA93E66 | — | — | 0.877 |
| 3 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.866 |
| 4 | SRR934819 | — | — | 0.854 |
| 5 | SRR934762 | — | — | 0.853 |
| 6 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.848 |
| 7 | 9C30E1C0-1ADE-460B-B53D-297CCA80C071 | — | — | 0.845 |
| 8 | SRR934788 | — | — | 0.844 |
| 9 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.842 |
| 10 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.351 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.325 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.291 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.289 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.284 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.274 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.273 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.267 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.259 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.257 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.252 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.237 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.232 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.227 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.226 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.221 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.179 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.174 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |